Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous dendritic cell vaccine (IRST) (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori")
- Development stage
- Unknown
- Lead developer
- IRST IRCCS
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
The autologous dendritic cell vaccine developed by the Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" is an investigational cell-based immunotherapy designed for the treatment of refractory microsatellite-stable (MSS) or mismatch repair-proficient (pMMR) metastatic colorectal cancer. This personalized biologic is produced by harvesting a patient's own dendritic cells and loading them with tumor-associated antigens to stimulate a targeted immune response. The vaccine aims to convert immunologically "cold" tumors into "hot" ones by priming T-lymphocytes to recognize and attack cancer cells. It is currently being evaluated in the Phase II CombiCoR-Vax trial (NCT06522919) as part of a sequential immunochemotherapy regimen that includes pembrolizumab induction followed by maintenance therapy with trifluridine/tipiracil and bevacizumab.
- Other names
- Autologous Dendritic Cell VaccineDC VaccineCombiCoR-Vax vaccine
Beyond the preview
Go deeper on autologous dendritic cell vaccine (IRST) (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori").
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous dendritic cell vaccine (IRST) (Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori").